Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | AKT2 | P31751 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | GRK2 | P25098 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14290338 | 0.87 | AKT1 (0.40) | GGPS1FDPSAKT1AKT2DPP4 | |
| SCHEMBL4716274 | 0.79 | GGPS1 (0.40) | GGPS1FDPSALDH1A1KDM4E | |
| SCHEMBL4720762 | 0.78 | ALDH1A1 (0.42) | GGPS1FDPSALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4714556 | 0.77 | HTT (0.36) | GGPS1FDPSALDH1A1KDM4EKMT2A | |
| SCHEMBL4716835 | 0.73 | GGPS1 (0.58) | GGPS1FDPS | |
| SCHEMBL2265948 | 0.69 | PRMT5 (0.42) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4714601 | 0.69 | ALDH1A1 (0.40) | GGPS1FDPSALDH1A1MEN1KMT2A | |
| SCHEMBL20926916 | 0.68 | FDPS (0.62) | GGPS1FDPSALDH1A1KDM4E | |
| SCHEMBL4718550 | 0.67 | PLA2G1B (0.40) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL20985887 | 0.66 | GGPS1 (0.42) | GGPS1FDPSALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448561-B1 | BETA 3 ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7265127-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7253181-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7241772-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7205407-B2 | 3-Substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7071208-B2 | β3 Adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| EP-1448560-B1 | 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020618-A1 | Beta 3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| US-20050020617-A1 | 3-substituted oxindole beta3 agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| EP-1448560-A1 | 3-SUBSTITUTED OXINDOLE $g(b)3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1448561-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003044016-A1 | 3-SUBSTITUTED OXINDOLE β3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003044017-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | GGPS1 2897/4885FDPS 4473/4885AKT1 1558/4885 |
| US-20050020618-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | GGPS1 2897/4885FDPS 4473/4885AKT1 1558/4885 |
| US-20050020617-A1 | 3-substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRA2C | GGPS1 3528/4885FDPS 4720/4885AKT1 2682/4885 |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | GGPS1 2897/4885FDPS 4473/4885AKT1 1558/4885 |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | GGPS1 2505/4885FDPS 4391/4885AKT1 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.